Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma
Clinical trial NCT02200562 · TERMINATED
Trial details
- NCT number
- NCT02200562
- Sponsor
- University of Utah
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-12-01
- Primary completion
- 2017-01-20
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.